Comparative Pharmacology
Head-to-head clinical analysis: RABEPRAZOLE SODIUM versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RABEPRAZOLE SODIUM versus ZEGERID.
RABEPRAZOLE SODIUM vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor (PPI) that inhibits the gastric H+/K+-ATPase enzyme at the secretory surface of gastric parietal cells, thereby suppressing basal and stimulated gastric acid secretion. It is a substituted benzimidazole that accumulates in the acidic environment of the parietal cell and is protonated, forming a covalent disulfide bond with cysteine residues of the proton pump, leading to irreversible inhibition.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
Oral: 20 mg once daily; duodenal ulcer: 20 mg once daily for up to 4 weeks; erosive esophagitis: 20 mg once daily for 4 to 8 weeks; GERD: 20 mg once daily for 4 to 8 weeks; Helicobacter pylori eradication: 20 mg twice daily in combination with antibiotics.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
1-2 hours in most individuals, but pharmacodynamic half-life is longer (24-48 hours) due to irreversible binding to proton pumps; clearance is reduced in hepatic impairment (half-life up to 12 hours)
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Primarily renal (approx. 90% as metabolites, <1% unchanged) and fecal (approx. 10%)
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor